Paris, 17 March 2026: at a press conference, REGENLIFE announced that it had reached a new key milestone in the clinical development of its technology for Alzheimer’s disease. This French medtech company, which specialises in the research and development of innovative photobiomodulation and neuromodulation technologies for the prevention and treatment of neurodegenerative diseases, is opening a new clinical trial centre at the Hospices Civils de Lyon — Lyon University Hospital, Hôpital des Charpennes. This new site marks a further step towards speeding up the recruitment of the study’s 108 patients, aged between 55 and 85 and suffering from mild to moderate Alzheimer’s disease. The study, led nationally by the principal investigator, Dr Julien Delrieu, now benefits from the local expertise of Dr Antoine Garnier-Crussard, a geriatrician at the CMRR at Lyon University Hospital.